Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors
Open Access
- 4 December 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Neuropathologica Communications
- Vol. 6 (1), 134
- https://doi.org/10.1186/s40478-018-0630-1
Abstract
Extensive molecular analyses of ependymal tumors have revealed that supratentorial and posterior fossa ependymomas have distinct molecular profiles and are likely to be different diseases. The presence of C11orf95-RELA fusion genes in a subset of supratentorial ependymomas (ST-EPN) indicated the existence of molecular subgroups. However, the pathogenesis of RELA fusion-negative ependymomas remains elusive. To investigate the molecular pathogenesis of these tumors and validate the molecular classification of ependymal tumors, we conducted thorough molecular analyses of 113 locally diagnosed ependymal tumors from 107 patients in the Japan Pediatric Molecular Neuro-Oncology Group. All tumors were histopathologically reviewed and 12 tumors were re-classified as non-ependymomas. A combination of RT-PCR, FISH, and RNA sequencing identified RELA fusion in 19 of 29 histologically verified ST-EPN cases, whereas another case was diagnosed as ependymoma RELA fusion-positive via the methylation classifier (68.9%). Among the 9 RELA fusion-negative ST-EPN cases, either the YAP1 fusion, BCOR tandem duplication, EP300-BCORL1 fusion, or FOXO1-STK24 fusion was detected in single cases. Methylation classification did not identify a consistent molecular class within this group. Genome-wide methylation profiling successfully sub-classified posterior fossa ependymoma (PF-EPN) into PF-EPN-A (PFA) and PF-EPN-B (PFB). A multivariate analysis using Cox regression confirmed that PFA was the sole molecular marker which was independently associated with patient survival. A clinically applicable pyrosequencing assay was developed to determine the PFB subgroup with 100% specificity using the methylation status of 3 genes, CRIP1, DRD4 and LBX2. Our results emphasized the significance of molecular classification in the diagnosis of ependymomas. RELA fusion-negative ST-EPN appear to be a heterogeneous group of tumors that do not fall into any of the existing molecular subgroups and are unlikely to form a single category.Keywords
Funding Information
- Japan Society for the Promotion of Science (16K10775, 17K15659)
- Japan Agency for Medical Research and Development (JP17ck0106168)
This publication has 38 references indexed in Scilit:
- Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trialJournal of Neuro-Oncology, 2013
- Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysisNeuro-Oncology, 2012
- IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapyInternational Journal of Oncology, 2012
- Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), Société Française d'Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP)Clinical Cancer Research, 2012
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeNature, 2012
- TopHat-Fusion: an algorithm for discovery of novel fusion transcriptsGenome Biology, 2011
- Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa EpendymomaCancer Cell, 2011
- Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohortsJournal of Negative Results in BioMedicine, 2011
- The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factorsLaboratory Investigation, 2008
- Human Telomere Reverse Transcriptase Expression Predicts Progression and Survival in Pediatric Intracranial EpendymomaJournal of Clinical Oncology, 2006